Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients - Related Studies

Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients

This study has been terminated.

Study NCT00445328. Last updated on October 30, 2008. Information provided by Pfizer

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Venous Thromboembolism

2	Additional conditions recognized in this trial
		Thromboembolism

3	More general conditions related to this trial
		Cardiovascular Diseases
		Embolism and Thrombosis
		Thrombosis
		Vascular Diseases

4	Interventions listed in this trial
		Dalteparin (Fragmin)
		Unfractionated heparin

5	Additional drug interventions recognized in this trial
		Dalteparin
		Heparin
		Heparin, Low-Molecular-Weight

6	More general drug interventions related to this trial
		Anticoagulants
		Cardiovascular Agents
		Fibrin Modulating Agents
		Fibrinolytic Agents
		Hematologic Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Therapeutic Uses

7	Sponsors listed in this trial
		Pfizer